Antithrombogenic materials

• US 5,028,597 A
• Filed: 04/13/1990
• Issued: 07/02/1991
• Est. Priority Date: 04/07/1986
• Status: Expired due to Term

• Current Assignee: Daiichi Pharmaceutical Company Limited (Daiichi Sankyo Company Limited), Agency of Industrial Science & Technology (Government of Japan), Sumitomo Electric Industries Limited (Sumitomo Corporation), Watanabe Pharmaceutical Industry Company Limited
• Original Assignee: Agency of Industrial Science & Technology (Government of Japan), Sumitomo Electric Industries Limited (Sumitomo Corporation), Watanabe Pharmaceutical Industry Company Limited
• Inventors: Sakai, Tsukasa, Kodama, Makoto, Oinuma, Hiroshi, Komamiya, Masaharu, Tsuda, Keishiro, Okita, Koichi, Asako, Shigeru
• Primary Examiner(s): Naff, David M.
• Assistant Examiner(s): Witz, Jean C.
• Application Number:
  US07/515,768
• Time in Patent Office: 445 Days
• Field of Search: 514/54, 514/56, 514/21, 623/1, 623/11, 623/12, 128/DIG. 8
• US Class Current: 514/56
• CPC Class Codes: A61L 33/0029 using an intermediate layer of polymer
• CPC Class Codes: A61L 33/062 Mixtures of macromolecular compounds
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin
• CPC Class Codes: Y10S 128/08 Collagen

Abstract

An antithrombogenic material is described, comprising an expanded polytetrafluoroethylene base having a collagen layer provided on the surface thereof, and further provided thereon a composite layer of collagen and a mucopolysaccharide, and said collagen is crosslinked with a crosslinking agent.

Claims

1. An antithrombogenic material consisting essentially of an expanded polytetrafluroethylene base having a collagen layer provided on the surface thereof, and a composite layer of collagen having mucopolysaccharide dispersed therein, provided on said collagen layer, wherein the collagen in said collagen layer and said composite layer is crosslinked with a crosslinking agent.

2. An antithrombogenic material as in claim 1, wherein said crosslinking agent is a polyvalent aldehyde compound.

3. An antithrombogenic material as in claim 2, wherein said polyvalent aldehyde compound is selected from at least one member of the group consisting of glutaraldehyde and dialdehyde starch.

4. An antithrombogenic material as in claim 1, wherein said mucopolysaccharide is selected from the group consisting of heparin, hyaluronic acid, chondroitin sulfate, and a mixture thereof.